RU2018105485A3 - - Google Patents

Download PDF

Info

Publication number
RU2018105485A3
RU2018105485A3 RU2018105485A RU2018105485A RU2018105485A3 RU 2018105485 A3 RU2018105485 A3 RU 2018105485A3 RU 2018105485 A RU2018105485 A RU 2018105485A RU 2018105485 A RU2018105485 A RU 2018105485A RU 2018105485 A3 RU2018105485 A3 RU 2018105485A3
Authority
RU
Russia
Application number
RU2018105485A
Other languages
Russian (ru)
Other versions
RU2018105485A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018105485A publication Critical patent/RU2018105485A/ru
Publication of RU2018105485A3 publication Critical patent/RU2018105485A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018105485A 2012-11-29 2018-02-14 Ингибирующие олигонуклеотиды и их применение RU2018105485A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/085547 2012-11-29
PCT/CN2012/085547 WO2014082254A1 (en) 2012-11-29 2012-11-29 Inhibitory oligonucleotide and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015120365A Division RU2015120365A (ru) 2012-11-29 2012-11-29 Ингибирующие олигонуклеотиды и их применение

Publications (2)

Publication Number Publication Date
RU2018105485A RU2018105485A (ru) 2019-08-14
RU2018105485A3 true RU2018105485A3 (OSRAM) 2019-08-14

Family

ID=50827048

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015120365A RU2015120365A (ru) 2012-11-29 2012-11-29 Ингибирующие олигонуклеотиды и их применение
RU2018105485A RU2018105485A (ru) 2012-11-29 2018-02-14 Ингибирующие олигонуклеотиды и их применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2015120365A RU2015120365A (ru) 2012-11-29 2012-11-29 Ингибирующие олигонуклеотиды и их применение

Country Status (10)

Country Link
US (2) US9688992B2 (OSRAM)
JP (1) JP6106280B2 (OSRAM)
KR (1) KR102027023B1 (OSRAM)
AU (1) AU2012395641B2 (OSRAM)
CA (1) CA2891906A1 (OSRAM)
MX (1) MX369618B (OSRAM)
PH (1) PH12015501182B1 (OSRAM)
RU (2) RU2015120365A (OSRAM)
SG (1) SG11201504142WA (OSRAM)
WO (1) WO2014082254A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014082254A1 (en) 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof
CN108431228A (zh) * 2015-12-25 2018-08-21 Sbi生物技术有限公司 Tlr抑制性寡核苷酸及其用途
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3468605A4 (en) * 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
JP7145853B2 (ja) * 2016-11-09 2022-10-03 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 適応免疫調節のための方法および組成物
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
CN112798796B (zh) * 2021-01-04 2024-02-02 东南大学 一种基于dna-paint的细胞膜上pd-l1蛋白检测方法及序列
WO2022170396A1 (en) * 2021-02-12 2022-08-18 ViraLok Therapeutics Pty Ltd Agents and methods for therapy and prophylaxis
CN116370494A (zh) * 2022-11-14 2023-07-04 南昌大学 CpG寡核苷酸对糖尿病神经病理痛疾病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072290A2 (en) 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
CN102851295B (zh) 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
US8030289B2 (en) 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
CN101643496B (zh) 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
CA2762206C (en) 2009-06-01 2017-06-27 Idera Pharmaceuticals, Inc. Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
WO2014082254A1 (en) 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof

Also Published As

Publication number Publication date
SG11201504142WA (en) 2015-06-29
JP6106280B2 (ja) 2017-03-29
AU2012395641B2 (en) 2019-10-03
US20150299710A1 (en) 2015-10-22
RU2018105485A (ru) 2019-08-14
RU2015120365A (ru) 2017-01-10
JP2015536659A (ja) 2015-12-24
PH12015501182A1 (en) 2015-08-17
MX369618B (es) 2019-11-14
AU2012395641A1 (en) 2015-05-28
US9688992B2 (en) 2017-06-27
CA2891906A1 (en) 2014-06-05
MX2015006703A (es) 2015-08-05
PH12015501182B1 (en) 2018-10-03
US10190122B2 (en) 2019-01-29
KR20150089019A (ko) 2015-08-04
US20170335325A1 (en) 2017-11-23
KR102027023B1 (ko) 2019-09-30
WO2014082254A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
BR112014017635A2 (OSRAM)
BR112014017614A2 (OSRAM)
BR112014017625A2 (OSRAM)
BR112014017659A2 (OSRAM)
BR112014017592A2 (OSRAM)
BR112014017638A2 (OSRAM)
AR092201A1 (OSRAM)
BR112014017609A2 (OSRAM)
BR112014017644A2 (OSRAM)
BR112014017634A2 (OSRAM)
BR112014017647A2 (OSRAM)
BR112014013184A8 (OSRAM)
BR112014017627A2 (OSRAM)
BR112014017623A2 (OSRAM)
BR112014023138A2 (OSRAM)
BR112014017630A2 (OSRAM)
BR112014017621A2 (OSRAM)
BR112014017631A2 (OSRAM)
BR112014017641A2 (OSRAM)
BR112014017622A2 (OSRAM)
BR112014018557A2 (OSRAM)
BR112014017600A2 (OSRAM)
BR112014017636A2 (OSRAM)
BR112014017667A2 (OSRAM)
BR112014017927A2 (OSRAM)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200310